You are here: Industry Insights > Scipher

News List

Scipher Medicine Increases Patient Access for PrismRA® by Expanding Intended Use in Autoimmune Patients b3cnewswire
July 30, 2021
Scipher Medicine, a precision immunology company matching patients with most effective therapy, today announced the expanded clinical utility and intended use to include most rheumatoid arthritis (RA) patients for its commercially available PrismRA.
Scipher Medicine Announces PrismRA® Met Primary and Secondary Endpoints in Prospective Observational Study Predicting Inadequate Response to World’s Largest-Selling Drug Class b3cnewswire
June 25, 2021
Scipher Medicine today announced positive results from a multicenter, blinded prospective observational clinical study assessing the ability of the PrismRA test to predict which patients with rheumatoid arthritis
Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test b3cnewswire
June 16, 2021
Scipher today announced that in an independent validation study, PrismRA accurately predicted which patients with rheumatoid arthritis would not achieve EULAR good response criteria at six months of treatment using either adalimumab or etanercept.
Scipher Medicine identifies new Covid-19 drug discovery approach pharmaceutical-technology
June 10, 2021
Scipher Medicine and its partners have identified a new approach that could cut the Covid-19 drug discovery timeline from years to months.
Galapagos signs deal with Scipher for IBD drug development pharmatimes
August 17, 2020
Belgium-based biotech Galapagos has signed a collaboration deal with Scipher Medicine to advance novel drug targets for the treatment of inflammatory bowel disease (IBD).